Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab rav...

Descripción completa

Detalles Bibliográficos
Autores principales: Schönfeld, Kurt, Zuber, Chantal, Pinkas, Jan, Häder, Thomas, Bernöster, Katrin, Uherek, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225632/
https://www.ncbi.nlm.nih.gov/pubmed/28077160
http://dx.doi.org/10.1186/s13045-016-0380-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225632/
https://www.ncbi.nlm.nih.gov/pubmed/28077160
http://dx.doi.org/10.1186/s13045-016-0380-0

Ejemplares similares